Coagulopathy in COVID-19 and Its Implication for Safe and Efficacious Thromboprophylaxis
Standard
Coagulopathy in COVID-19 and Its Implication for Safe and Efficacious Thromboprophylaxis. / Langer, Florian; Kluge, Stefan; Klamroth, Robert; Oldenburg, Johannes.
in: HAMOSTASEOLOGIE, Jahrgang 40, Nr. 3, 08.2020, S. 264-269.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Coagulopathy in COVID-19 and Its Implication for Safe and Efficacious Thromboprophylaxis
AU - Langer, Florian
AU - Kluge, Stefan
AU - Klamroth, Robert
AU - Oldenburg, Johannes
N1 - Georg Thieme Verlag KG Stuttgart · New York.
PY - 2020/8
Y1 - 2020/8
N2 - The novel coronavirus, SARS-CoV-2, is causing a global pandemic of life-threatening multiorgan disease, called COVID-19. Accumulating evidence indicates that patients with COVID-19 are at significant risk of thromboembolic complications, mainly affecting the venous, but also the arterial vascular system. While the risk of venous thromboembolism (VTE) appears to be higher in patients requiring intensive care unit support compared to those admitted to general wards, recent autopsy findings and data on the timing of VTE diagnosis relative to hospitalization clearly suggest that thromboembolic events also contribute to morbidity and mortality in the ambulatory setting. In addition to a severe hypercoagulable state caused by systemic inflammation and viral endotheliitis, some patients with advanced COVID-19 may develop a coagulopathy, which meets established laboratory criteria for disseminated intravascular coagulation, but is not typically associated with relevant bleeding. Similar to other medical societies, the Society of Thrombosis and Haemostasis Research has issued empirical recommendations on initiation, dosing, and duration of pharmacological VTE prophylaxis in COVID-19 patients.
AB - The novel coronavirus, SARS-CoV-2, is causing a global pandemic of life-threatening multiorgan disease, called COVID-19. Accumulating evidence indicates that patients with COVID-19 are at significant risk of thromboembolic complications, mainly affecting the venous, but also the arterial vascular system. While the risk of venous thromboembolism (VTE) appears to be higher in patients requiring intensive care unit support compared to those admitted to general wards, recent autopsy findings and data on the timing of VTE diagnosis relative to hospitalization clearly suggest that thromboembolic events also contribute to morbidity and mortality in the ambulatory setting. In addition to a severe hypercoagulable state caused by systemic inflammation and viral endotheliitis, some patients with advanced COVID-19 may develop a coagulopathy, which meets established laboratory criteria for disseminated intravascular coagulation, but is not typically associated with relevant bleeding. Similar to other medical societies, the Society of Thrombosis and Haemostasis Research has issued empirical recommendations on initiation, dosing, and duration of pharmacological VTE prophylaxis in COVID-19 patients.
KW - Anticoagulants/therapeutic use
KW - Autopsy/statistics & numerical data
KW - Betacoronavirus/isolation & purification
KW - Blood Coagulation Disorders/epidemiology
KW - COVID-19
KW - Case-Control Studies
KW - China/epidemiology
KW - Coronavirus Infections/complications
KW - Disseminated Intravascular Coagulation/blood
KW - Heparin, Low-Molecular-Weight/therapeutic use
KW - Hospitalization
KW - Humans
KW - Pandemics
KW - Pneumonia, Viral/complications
KW - SARS-CoV-2
KW - Survivors/statistics & numerical data
KW - Systemic Inflammatory Response Syndrome/physiopathology
KW - Thrombophilia/etiology
KW - Venous Thromboembolism/drug therapy
U2 - 10.1055/a-1178-3551
DO - 10.1055/a-1178-3551
M3 - SCORING: Review article
C2 - 32498097
VL - 40
SP - 264
EP - 269
JO - HAMOSTASEOLOGIE
JF - HAMOSTASEOLOGIE
SN - 0720-9355
IS - 3
ER -